Macquarie Group Ltd. raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 3.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 105,159 shares of the medical research company’s stock after buying an additional 3,625 shares during the period. Macquarie Group Ltd.’s holdings in Amgen were worth $16,000,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its stake in shares of Amgen by 99.1% in the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 102,511 shares of the medical research company’s stock worth $15,583,000 after buying an additional 51,025 shares during the period. Badgley Phelps & Bell Inc. boosted its stake in shares of Amgen by 76.9% in the second quarter. Badgley Phelps & Bell Inc. now owns 49,799 shares of the medical research company’s stock worth $7,577,000 after buying an additional 21,649 shares during the period. Parsec Financial Management Inc. boosted its stake in shares of Amgen by 2.2% in the second quarter. Parsec Financial Management Inc. now owns 86,538 shares of the medical research company’s stock worth $13,167,000 after buying an additional 1,861 shares during the period. Nationwide Fund Advisors boosted its stake in shares of Amgen by 3.7% in the second quarter. Nationwide Fund Advisors now owns 631,839 shares of the medical research company’s stock worth $96,134,000 after buying an additional 22,751 shares during the period. Finally, PGGM Investments boosted its stake in shares of Amgen by 9.7% in the second quarter. PGGM Investments now owns 725,684 shares of the medical research company’s stock worth $110,413,000 after buying an additional 64,011 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) traded up 0.02% on Monday, reaching $145.46. 1,475,131 shares of the company’s stock were exchanged. Amgen Inc. has a one year low of $133.64 and a one year high of $176.85. The stock has a market cap of $108.21 billion, a price-to-earnings ratio of 14.56 and a beta of 1.15. The firm has a 50 day moving average of $151.65 and a 200-day moving average of $160.47.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.79 by $0.23. The business earned $5.81 billion during the quarter, compared to analysts’ expectations of $5.73 billion. Amgen had a return on equity of 29.27% and a net margin of 33.63%. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.72 earnings per share. Equities research analysts forecast that Amgen Inc. will post $11.56 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 8th. Investors of record on Wednesday, November 16th will be paid a $1.00 dividend. This represents a $4.00 annualized dividend and a dividend yield of 2.75%. The ex-dividend date of this dividend is Monday, November 14th. Amgen’s dividend payout ratio (DPR) is currently 39.92%.

ILLEGAL ACTIVITY NOTICE: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright and trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/28/macquarie-group-ltd-raises-position-in-amgen-inc-amgn.html.

A number of analysts have recently issued reports on the stock. Leerink Swann set a $163.00 price objective on shares of Amgen and gave the stock a “hold” rating in a research note on Monday, November 21st. Vetr cut shares of Amgen from a “strong-buy” rating to a “buy” rating and set a $167.77 price objective for the company. in a research note on Thursday, November 10th. Mizuho assumed coverage on shares of Amgen in a research note on Monday, November 7th. They issued a “buy” rating and a $164.00 price objective for the company. RBC Capital Markets set a $190.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research note on Sunday, October 30th. Finally, Jefferies Group restated a “buy” rating on shares of Amgen in a research report on Wednesday, September 28th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the stock. Amgen currently has an average rating of “Buy” and a consensus price target of $182.04.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.